Photo collage of Jonathan Riess and David Gandara
Aug 27, 2024, 21:52
David Gandara: Jonathan Riess about impact of baseline positive vs negative plasma ctDNA
David Gandara, Co-Director-Center for Experimental Therapeutics at UC Davis Comprehensive Cancer Center, shared a post on X:
“At Cal Cancer Consortium conference, Jonathan Riess shows impact of baseline positive vs negative plasma ctDNA for EGFR in the FLAURA2 trial. Addition of chemo to Osi mainly benefitting those with positive ctDNA. Food for thought!”
Source: David Gandara/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 22, 2025, 16:27
Mar 22, 2025, 14:55
Mar 22, 2025, 14:41
Mar 22, 2025, 14:28
Mar 22, 2025, 13:46
Mar 22, 2025, 13:29
Mar 22, 2025, 13:16
Mar 22, 2025, 12:47
Mar 22, 2025, 12:27